Abstract 418P
Background
Mutational landscape studies, facilitated by next-generation sequencing technologies, can improve our understanding of cancer pathogenesis and help identify potentially targetable alterations. In this study, we aimed to provide an overall description of the mutational landscape in non-small cell lung cancer (NSCLC) using publicly available sequencing data.
Methods
We used the American Association for Cancer Research’s Project Genomics Evidence Neoplasia Information Exchange (GENIE) [GENIE Cohort v11.0-public study] to obtain sequencing data for patients diagnosed with NSCLC. Mutational profiles were described according to race (White, Black, or Asian) and histopathology (adenocarcinoma or squamous cell carcinoma). We used the OncoKB to assess the actionability of frequently mutated genes in the studied cohort.
Results
We included 16,498 samples (13,927 White, 1,304 Black, and 1,267 Asian; 12,790 adenocarcinoma, and 1,546 squamous cell carcinoma). TP53 was the most frequently mutated gene, with half of the analyzed samples (49.6%) containing at least one TP53-related molecular alteration. TP53 mutation rate was higher in cases with squamous cell carcinoma compared to cases with adenocarcinoma (76.7% vs. 45.6%; p<0.001). In race-dependent subgroup analysis, mutations in EGFR gene occurred in about 53.3% of Asian cases to rank as the most frequently mutated gene in this subgroup (Table). Most of the frequently mutated genes in NSCLC (especially in the squamous cell carcinoma subgroup) are still not actionable (Table). Table: 418P
Commonly mutated genes in NSCLC
Adenocarcinoma | Squamous Cell | White | Black | Asian |
TP53 (45.6%) | TP53 (76.6%) | TP53 (49.2%) | TP53 (55.7%) | EGFR (53.3%) * |
KRAS (32.2%) * | KMT2D (22.1%) | KRAS (30%) * | PCM1 (25%) | TP53 (48.2%) |
EGFR (25.8%) * | PRKDC (11.5%) | EGFR (18.8%) * | KRAS (24.8%) * | KRAS (10.6%) * |
KEAP1 (13.5%) | PCM1 (11.3%) | KEAP1 (14.6%) | EGFR (20.6%) * | RBM10 (9.5%) |
SKT11 (13.1%) * | KEAP1 (11%) | LRP1B (13%) | KEAP1 (11.8%) | KMT2D (6.9%) |
* gene with actionable mutation(s)
Conclusions
Despite progress in the targetability of NSCLC, many of the most frequently mutated genes are still not actionable. Genomic profiling has the potential to identify potential targets of interest, which could guide individualized treatment plans to address the current high burden of NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
440P - Targeting KRAS<sup>G12C</sup>: Repurposing of potential therapeutics for the treatment of pancreatic ductal adenocarcinoma (PDAC)
Presenter: EVA RAHMAN KABIR
Session: Poster viewing 06
441P - Malignant diseases diagnosed in people living with HIV in Japan
Presenter: Kenju Ando
Session: Poster viewing 06
442P - Dose intensity and tolerance of modified FOLFIRINOX in patients with advanced cancer
Presenter: Tejaswini Adadadara
Session: Poster viewing 06
444P - Incidence of cancer diagnosis and cancer care before and after the COVID-19 pandemic in French Polynesia TEAHUPOO study
Presenter: Elodie HIRIGOYEN
Session: Poster viewing 06
445P - Development of a simple and objective prognostication model in patients with advanced solid malignant tumor treated with immune checkpoint inhibitors: A pan-cancer analysis
Presenter: Yuto Matsushita
Session: Poster viewing 06
446P - Impact of previous immunotherapy on chemotherapy efficacy in metastatic melanoma
Presenter: Meiyu Fang
Session: Poster viewing 06
447P - Clinical characteristics of 21 patients with type 1 diabetes mellitus related to immune checkpoint inhibitors
Presenter: Haruna Kameoka
Session: Poster viewing 06
448P - Prevalence of thyroid dysfunction, diabetes, and impact of palliative chemotherapy in advanced metastatic cancer patients: Prospective data from LMIC
Presenter: Amit Sehrawat
Session: Poster viewing 06
449P - The study of androgen receptor status in triple negative breast cancer patients at Medical Oncology Department, Yangon General Hospital (YGH)
Presenter: Khin Mu
Session: Poster viewing 06
450P - Are grade III well-differentiated neuroendocrine tumours a unique clinic-pathological entity?
Presenter: Jahnavi Kalvala
Session: Poster viewing 06